Compare Mesoblast Limited (MESO) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Smith & Nephew plc — how do they compare? Mesoblast Limited trades at $17.03 (market cap $2.21B), while Smith & Nephew plc trades at $29.72 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 5.7× Mesoblast Limited's market cap, and Smith & Nephew plc pays a 2.65% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SNN | |
|---|---|---|
Market Cap | $2.21B | $12.54B |
Sector | Technology | Health |
52-Week High | $20.96 | $38.70 |
52-Week Low | $12.88 | $28.73 |
Enterprise Value | $2.21B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
